Immunovant, Inc. (IMVT)
NASDAQ: IMVT · IEX Real-Time Price · USD
26.52
-0.99 (-3.60%)
At close: Jul 2, 2024, 4:00 PM
26.02
-0.50 (-1.89%)
After-hours: Jul 2, 2024, 7:56 PM EDT
Immunovant Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
207
Market Cap
3.88B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 0 | - | - |
| Mar 31, 2023 | 0 | - | - |
| Mar 31, 2022 | 0 | - | - |
| Mar 31, 2021 | 0 | - | - |
| Mar 31, 2020 | 0 | - | - |
| Mar 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alkermes | 1.73B |
| Integer Holdings | 1.63B |
| Waystar Holding | 747.13M |
| Inspire Medical Systems | 660.91M |
| Guardant Health | 603.73M |
| Ultragenyx Pharmaceutical | 442.59M |
| Axsome Therapeutics | 251.02M |
| Merus | 38.34M |
IMVT News
- 4 weeks ago - Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 - GlobeNewsWire
- 4 months ago - Immunovant Awarded U.S. Patent for IMVT-1402 - GlobeNewsWire
- 5 months ago - Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023 - GlobeNewsWire
- 6 months ago - Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 months ago - Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease - GlobeNewsWire
- 7 months ago - Best Small-Cap Stocks to Buy for 2024 and Beyond - Kiplinger
- 7 months ago - Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential - GlobeNewsWire
- 8 months ago - Immunovant to Present at Upcoming Investor Conferences - GlobeNewsWire